Abstract: A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.

Abstract: A solid cosmetic composition includes (i) a natural colourant, (ii) starch, and (iii) mica.

Abstract: A composition for forming an air dry soft nail coating comprising an alkyl (meth)acrylate polymer and a volatile solvent after an application of the composition to a nail forms a soft nail coating. Such soft nail coating is suitable for use in preparing a mirror effect on a nail. Further, the present invention also relates to a nail coating comprising at least the soft nail coating and a powder layer. These two layers are central to a method of forming a mirror like effect on nails. A multilayer laminate nail coating comprising the bilayer, a top coat layer, and optionally a base coat layer is also taught.

Abstract: The present invention relates to a hair styling and restyling composition comprising a cosmetically acceptable pressure sensitive adhesive polymer with restyling performance and improved washout from hair, to a pressure sensitive adhesive polymer with glass transition temperatures of lower than ?20° C., to a process for preparing said pressure sensitive adhesive polymer and to use of said pressure sensitive adhesive polymer for improving the restylability and washout behavior of a hair styling and restyling composition.

Abstract: The present invention relates to the cosmetic of a Diospyros mespiliformis extract alone or in combination with a Sanicula europea extract and/or a Furcellaria lumbricalis extract and/or a Lampsana communis extract to fight against and/or prevent the effects of pollution on the skin. The invention also relates to a cosmetic process for the cosmetic prevention or treatment of the effects of pollution on the skin consisting of applying a Diospyros mespiliformis extract, alone or in combination with other active agents, to the skin.

Abstract: The appearance of hyperpigmented lesions on human skin are reduced by applying a topical solution composition that includes a concentrated amount of resveratrol that has been extracted from red wine and is at a pH of between 2.5 and 5.5.

Abstract: A method of treating skin is disclosed. The method can include topically applying to skin an effective amount of a composition that has water, an extract comprising Crithmum maritimum, and an extract comprising Ulva lactuca, wherein the extract comprising Ulva lactuca includes a hydrolysate of Ulva lactuca proteins.

Abstract: A solid surfactant cosmetic composition includes (i) insoluble vegetable fibre, insoluble fruit fibre or mixture thereof; (ii) surfactant; and (iii) hydrocolloid. The solid surfactant cosmetic composition is prepared by dehydrating a liquid composition. The liquid composition includes (i) a vegetable pulp containing insoluble vegetable fibre, a fruit pulp containing insoluble fruit fibre or a mixture thereof, wherein the vegetable pulp, fruit pulp or mixture thereof is in an amount of 55 to 99 wt. %; (ii) surfactant in an amount of 0.9 to 40 wt. %; and (iii) hydrocolloid in an amount of 0.1 to 15 wt. %, the amounts being based on the total combined amount of pulp, surfactant and hydrocolloid.

Abstract: The present invention relates to the cosmetic use of a combination of a hydrolysed rice extract and a grapeseed extract as an active agent to protect cutaneous cells from pollution. The present invention relates also to a cosmetic method of treatment for protecting skin epidermal cells from atmospheric pollution comprising applying on the skin area to be treated a composition comprising a combination of a hydrolysed rice extract and a grapeseed extract.

Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.

Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminolycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.

Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Abstract: The present technology provides intravaginal devices designed to deliver lubricants to the vagina for a sustained period of time. The intravaginal devices include a first segment comprising an outer surface and a lumen containing a lubricant, wherein the first segment is configured to deliver the contents of the lumen to the outer surface, and the first segment comprises a polymer selected from the group consisting of a hydrophilic, semi-permeable elastomer and a hydrophobic elastomer. The lubricant may be an aqueous lubricant. The present technology further provides an intravaginal device including a solid first segment that includes a hydrophilic semi-permeable elastomer, an outer surface and an aqueous lubricant, wherein the first segment is configured to deliver the aqueous lubricant to the outer surface.

Abstract: The present invention relates to an oral film preparation obtained by spreading a solution containing a high potency drug and a film-forming polymer and then drying the solution, and a method for preparing an oral film preparation containing a high potency drug, said method comprising spreading a solution containing the high potency drug and a film-forming polymer and then drying the same, and a package obtained by (a) packaging the oral film preparation in a packaging material and, after nitrogen substitution, sealing the packaging material, and/or (b) sealing the oral film preparation together with a deoxidant in a packaging material. Provided are an oral film preparation that contains a high potency drug and has excellent content uniformity, a method for easily preparing an oral film preparation that contains a high potency drug and has excellent content uniformity, and a highly stable package that contains the oral film preparation.

Abstract: The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease.

Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.

Abstract: The present invention provides compositions and methods for treating epidermolysis bullosa.

Abstract: This invention is related to use of exosomes for biomarker analysis for early detecting and characterizing of disease progression of cancer. Further, the invention provides bioengineered exosomes for use in methods of targeting and treating cancer.

Abstract: Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.

Abstract: The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.

Abstract: Abuse deterrent pharmaceutical compositions, processes for their preparation and methods of use thereof are described. An exemplary composition is a solid oral pharmaceutical composition containing an active agent, a gelling agent in an amount of between about 0.7 and about 1.5% of the weight of the composition, and a channeling agent in an amount of at least about 40% of the weight of the composition. In one embodiment, the active agent is an opioid such as oxycodone. In one embodiment, the gelling agent is xanthan gum. The gelling agent deters the extractability of the drug from the composition. In another embodiment, the channeling agent is crospovidone. The channeling agent allows the immediate release of the active agent from the composition in the presence of the gelling agent. In a preferred embodiment, crospovidone is in an amount about 53.3% of the weight of the composition.

Abstract: The present disclosure provides powder coating compositions for pharmaceutical pellets which include one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95% w/w. The compositions include one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100° C. The compositions also include one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95% w/w as well as one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25% w/w.

Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.

Abstract: Dosing regimens for transdermal delivery of hormones comprising a five week treatment cycle with a fixed treatment interval and a fixed rest interval.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.

Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.

Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.

Abstract: The invention relates to a pharmaceutical combination comprising an SSAO/VAP-1 inhibitor according to the formula (I) wherein R1 to R6, and X are as defined herein, and an SGLT2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient.

Abstract: Niclosamide derivatives are provided in the present invention. More particularly, the methods of using niclosamide derivatives for the manufacture of medicaments for suppressing platelet aggregation and preventing thrombosis-related diseases are provided. The niclosamide derivatives in the medicaments inhibit the production of thromboxane A2, therefore suppress platelet aggregation and prevent thrombosis-related diseases.

Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.

Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.

Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Abstract: The present invention provides a mucosal immunostimulator comprising, as an active ingredient, at least one selected from the group consisting of saturated fatty acids represented by the following formula (1) and salts thereof: R—COOH??(1) wherein, in the formula (1), R represents an alkyl group having 7 to 11 carbon atoms substituted with one hydroxy group.

Abstract: Natural soap compositions and methods of manufacturing the same having anti-microbial properties for treating and preventing diaper rash and other microbial infections. The soap compositions may contain one or more fatty acids with carbon length ranging from four (C4) to twenty-two (C22) and/or natural fatty acid mixtures of coconut oil, olive oil, and/or tall oil fatty acids which are saponified with lye. The saponification lye may be sodium or potassium hydroxide. In preferred embodiments, the soap compositions contain at least one of sodium or potassium caprate, sodium or potassium caprylate, or mixtures thereof, especially 55:45% caprylate to caprate. The soap compositions are effective at treating or preventing diaper rashes and other microbial infections associated with Candida albicans (Ca—yeast), Pseudomonas aeruginosa (Psa—a Gram negative bacteria), Staphylococcus aureus (Sa—a Gram positive bacteria), and Aspergillus niger (An—a mold).

Abstract: The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.

Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Abstract: The present invention relates to methods of preventing a psychotic disorder in a subject in need of intervention including administering to the subject a composition including EPA (eicosapentanoic acid) and DHA (docosahexaenoic acid). Methods of treating pre-psychotic symptoms in a subject, including administering to the subject a composition including EPA and DHA are also included.

Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.

Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.

Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.

Abstract: The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage; and methods of treatment of primary and secondary hypertension, the secondary hypertension resulting from pheochromocytoma, primary hyperaldosteronism, adrenal hyperplasia, pulmonary hypertension, portal hypertension, folate deficiency hypertension, arterial hypertension or familial hypertension by administration between one and eight times per day.

Abstract: A method of treating disorders in a human or animal subject may include heating a material containing a compound to a first temperature to form a heated volume of the material. The method may additionally include heating the heated volume to a higher second temperature to form a dose of vapor including the compound. The method may also include administering the dose of vapor to the subject to treat disorders such as pain. The method may further include pre-heating the material to a preliminary temperature prior to the heating to the first temperature. The heating and pre-heating may be performed with a capsule including two covering layers, each including an electrically conductive material, configured to hold the material therebetween and to generate heat by resistive heating.

Abstract: A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

Abstract: Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.

Abstract: Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.

Abstract: A resuscitation composition is described herein, as are methods of making and using such a composition.

Abstract: Provided are a pharmaceutical composition including: an alpha 2 (?2)-adrenoceptor agonist; a regulator of G-protein signaling (RGS) inhibitor, an endocytosis inhibitor, or a combination thereof; and a pharmaceutically acceptable salt, and a method of relieving pain of a subject, the method including administering the pharmaceutical composition to a subject.